If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 221 - 230 of 263
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (ATHENA-SSc-ILD)
Protocol No
RHEU-PROMETHEUS-ATHENA
Categories
GORE ENFORM Biomaterial Product Study: A Study to Describe Multi-use Biomaterial Performance in Hernia Patients Undergoing Open Hernia Repair Procedures
Biomaterial Product Study
Protocol No
SURG-GORE-ENFORM
Categories
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy - The C-TRACT Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy
Protocol No
VIR-NIH-C-TRACT
Categories
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine with or without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)
Protocol No
PANBELA-CL-SBP-101-04
Categories
Phase II, Single-Arm, Open-Label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-cell Non-Hodgkins Lymphoma
Phase II Study Evaluating Adjunctive Zanubrutinib and CAR T-cell therapy in Aggressive B-cell Non-Hodgkins Lymphoma
Protocol No
NU-20H09-NHL
Categories
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Protocol No
NRG-GU009-PREDICT-RT
Categories
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Study of tandem, bispecific anti-CD19 anti-CD20 CAR-T cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Protocol No
IIT-SHAH-IL7-IL15-CD20-19
Categories
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Selinexor is a medicine that is FDA approved for other cancer but not for endometrial cancer (EC). Selinexor was investigated in a prior study and demonstrated promising activity in a subgroup of patients with TP53 wild-type EC. To date there are no approved treatment options in the maintenance setting for patients with advanced or recurrent EC following response to chemotherapy. In this research study, we will investigate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer.
Protocol No
GOG-3083-XPORT-EC-042SELINEXOR
Categories
A Phase 1, First-in-human (FIH), Dose-finding and Expansion Study to Evaluate the Safety and Tolerability of XmAb808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
A Phase 1 Study of XmAb808 in Select Advanced Solid Tumors
Protocol No
XENCOR-XMAB808-01
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Breast Cancers,
Lung,
Melanoma, Skin,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Ovary
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies
A Phase 1 Study if SGR-1505 in Patients with B-Cell Malignancies
Protocol No
SCHRODINGER-SGR-1505-101
Categories